<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.2 20060430//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Nucleic Acids Res</journal-id><journal-id journal-id-type="publisher-id">Nucleic Acids Research</journal-id><journal-title>Nucleic Acids Research</journal-title><issn pub-type="ppub">0305-1048</issn><issn pub-type="epub">1362-4962</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.1093/nar/gkl389</article-id><article-id pub-id-type="pmid">16757575</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Hepatitis B virus X protein and the estrogen receptor variant lacking exon 5 inhibit estrogen receptor signaling in hepatoma cells</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Han</surname><given-names>Juqiang</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ding</surname><given-names>Lihua</given-names></name></contrib><contrib contrib-type="author"><name><surname>Yuan</surname><given-names>Bin</given-names></name></contrib><contrib contrib-type="author"><name><surname>Yang</surname><given-names>Xiao</given-names></name></contrib><contrib contrib-type="author"><name><surname>Wang</surname><given-names>Xiaohui</given-names></name></contrib><contrib contrib-type="author"><name><surname>Li</surname><given-names>Jiezhi</given-names></name></contrib><contrib contrib-type="author"><name><surname>Lu</surname><given-names>Qiujun</given-names></name><xref ref-type="aff" rid="au1">1</xref></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Cuifen</given-names></name></contrib><contrib contrib-type="author"><name><surname>Ye</surname><given-names>Qinong</given-names></name><xref ref-type="corresp" rid="cor1">*</xref></contrib><aff><institution>Beijing Institute of Biotechnology</institution><addr-line>27 Tai-Ping Lu Road, Beijing 100850, People's Republic of China</addr-line></aff><aff id="au1"><sup>1</sup><institution>Beijing Institute of Radiation Medicine</institution><addr-line>Beijing 100850, People's Republic of China</addr-line></aff></contrib-group><author-notes><corresp id="cor1"><sup>*</sup>To whom correspondence should be addressed. Tel: +8610 6818 0809; Fax: +8610 6824 8045; Email: <email>yeqn@nic.bmi.ac.cn</email></corresp></author-notes><!--For NAR: both ppub and collection dates generated for PMC processing 1/27/05 beck--><pub-date pub-type="collection"><year>2006</year></pub-date><pub-date pub-type="ppub"><year>2006</year></pub-date><pub-date pub-type="epub"><day>6</day><month>6</month><year>2006</year></pub-date><volume>34</volume><issue>10</issue><fpage>3095</fpage><lpage>3106</lpage><history><date date-type="received"><day>27</day><month>1</month><year>2006</year></date><date date-type="rev-recd"><day>17</day><month>4</month><year>2006</year></date><date date-type="accepted"><day>08</day><month>5</month><year>2006</year></date></history><copyright-statement>&#x000a9; 2006 The Author(s)</copyright-statement><copyright-year>2006</copyright-year><license license-type="openaccess"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/2.0/uk/"/>) which permits unrestricted non-commerical use, distribution, and reproduction in any medium, provided the original work is properly cited.</p></license><abstract><p>Hepatitis B virus (HBV) X protein (HBx) is considered to play a role in the development of hepatocellular carcinoma (HCC) during HBV infection. HCC was shown to be more prevalent in men than in women. Estrogen, which exerts its biological function through estrogen receptor (ER), can inhibit HBV replication. ER&#x00394;5, an ER&#x003b1; variant lacking exon 5, was found to be preferentially expressed in patients with HCC compared with patients with normal livers. Here, we report the biological role of ER&#x00394;5 and a novel link between HBx and ER&#x003b1; signaling in hepatoma cells. ER&#x00394;5 interacts with ER&#x003b1; <italic>in vitro</italic> and <italic>in vivo</italic> and functions as a dominant negative receptor. Both ER&#x003b1; and ER&#x00394;5 associate with HBx. HBx decreases ER&#x003b1;-dependent transcriptional activity, and HBx and ER&#x00394;5 have additive effect on suppression of ER&#x003b1; transactivation. The HBx deletion mutant that lacks the ER&#x003b1;-binding site abolishes the HBx repression of ER&#x003b1;. HBx, ER&#x003b1; and histone deacetylase 1 (HDAC1) form a ternary complex. Trichostatin A, a specific inhibitor of HDAC enzyme, can restore the transcriptional activity of ER&#x003b1; inhibited by HBx. Our data suggest that HBx and ER&#x00394;5 may play a negative role in ER&#x003b1; signaling and that ER&#x003b1; agonists may be developed for HCC therapy.</p></abstract></article-meta></front><body><sec><title>INTRODUCTION</title><p>Prolonged infection with Hepatitis B virus (HBV) has been clearly recognized as a major etiological factor for hepatocellular carcinoma (HCC) (<xref ref-type="bibr" rid="b1">1</xref>). HBx, a virally encoded protein of 154 amino acids, has been shown to have multifunctional activities relevant to HBV-mediated oncogenesis (<xref ref-type="bibr" rid="b2">2</xref>). HBx is involved in neoplastic transformation in cultured cells and can induce liver cancer in transgenic mice. Although HBx does not bind to double-stranded DNA, it regulates transcription of a variety of cellular and viral genes by interacting with cellular proteins and/or components of signal transduction pathways. HBx has been shown to interact with transcriptional factors such as RPB5 of RNA polymerase (<xref ref-type="bibr" rid="b3">3</xref>), TATA-binding protein (<xref ref-type="bibr" rid="b4">4</xref>), basic region/leucine zipper (bZIP) proteins (<xref ref-type="bibr" rid="b5">5</xref>) and the tumor suppressor p53 (<xref ref-type="bibr" rid="b6">6</xref>). Besides, it can also associate with serine protease TL2 (<xref ref-type="bibr" rid="b7">7</xref>) and cellular DNA repair protein (<xref ref-type="bibr" rid="b8">8</xref>). The interaction of HBx with these proteins leads to activation of signal transduction pathways including the Ras/Raf/mitogen-activated protein kinase, protein kinase C, Jak1-STAT and nuclear factor &#x003ba;B pathways (<xref ref-type="bibr" rid="b9">9</xref>&#x02013;<xref ref-type="bibr" rid="b12">12</xref>). However, the intracellular signaling pathways in which Hbx is involved are not fully elucidated.</p><p>Estrogen was shown to suppress HBV replication in male athymic mice transplanted with HBV-transfected HepG2 cells (<xref ref-type="bibr" rid="b13">13</xref>). The fact that HCC is more prevalent in men than in women suggests that estrogen may play an important role in the development of HCC (<xref ref-type="bibr" rid="b14">14</xref>&#x02013;<xref ref-type="bibr" rid="b17">17</xref>). Estrogen exerts its function through its two nuclear receptors, estrogen receptor &#x003b1; and &#x003b2; (ER&#x003b1; and ER&#x003b2;) (<xref ref-type="bibr" rid="b18">18</xref>&#x02013;<xref ref-type="bibr" rid="b21">21</xref>). ER&#x003b1; and ER&#x003b2; share structural similarity characterized by several functional domains. Two distinct activation function (AF) domains, AF-1 and AF-2, located at the N-terminus and the C-terminus, respectively, contribute to the transcriptional activity of the two receptors. The DNA-binding domain (DBD) of the two receptors is well conserved and centrally located. Activation of ERs is responsible for many biological processes, including cell growth, differentiation and apoptosis.</p><p>ER&#x003b1; has been well characterized in human liver (<xref ref-type="bibr" rid="b22">22</xref>). ER&#x003b1; is expressed in the liver of both healthy individuals and patients with HCC, with no differences in the pattern of expression (<xref ref-type="bibr" rid="b23">23</xref>,<xref ref-type="bibr" rid="b24">24</xref>). In contrast, the mutant form with the entire exon 5 deleted (ER&#x00394;5) is preferentially expressed in patients with HCC compared with patients with normal livers (<xref ref-type="bibr" rid="b25">25</xref>). The presence of the liver ER&#x00394;5 transcript in the tumor was the strongest negative predictor of survival in operable HCC (<xref ref-type="bibr" rid="b26">26</xref>&#x02013;<xref ref-type="bibr" rid="b28">28</xref>). Its presence also correlates with a higher clinical aggressiveness of the tumor in comparison with tumors characterized by wild-type ER&#x003b1; (wt ER&#x003b1;) transcript. High rates of ER&#x00394;5 expression have been shown to present in men at high-risk for HCC development. ER&#x00394;5 encodes the hormone-independent AF-1 domain, as well as the DBD. Although ER&#x00394;5 was demonstrated to be coexpressed with wt ER&#x003b1; in HCC, the role of ER&#x00394;5 in ER&#x003b1; signaling remains to be investigated.</p><p>On the basis of <italic>in vivo</italic> and <italic>in vitro</italic> functional relevance of the estrogen/ER&#x003b1; axis and HBx in the development of HCC, we hypothesized that HBx may play a role in ER&#x003b1; signaling. Here, we show that ER&#x00394;5 has a dominant negative activity in hepatoma cells when expressed together with wt ER&#x003b1;. HBx decreases ER&#x003b1; transcriptional activity, and HBx and ER&#x00394;5 have additive effect on inhibition of ER&#x003b1; transactivation. We further present <italic>in vitro</italic> and <italic>in vivo</italic> evidence that both HBx and ER&#x00394;5 interact with ER&#x003b1;. HBx inhibits ER&#x003b1; signaling possibly through recruitment of histone deacetylase 1 (HDAC1).</p></sec><sec sec-type="materials|methods"><title>MATERIALS AND METHODS</title><sec><title>Plasmids</title><p>The reporter constructs ERE-Luc (<xref ref-type="bibr" rid="b29">29</xref>), C3-LUC (<xref ref-type="bibr" rid="b30">30</xref>,<xref ref-type="bibr" rid="b31">31</xref>), pS2-LUC (<xref ref-type="bibr" rid="b32">32</xref>) and pS2&#x00394;ERE-LUC (<xref ref-type="bibr" rid="b33">33</xref>), and expression vector for ER&#x003b1; have been described previously. For the generation of FLAG-tagged full-length HBx, human HBx DNA was amplified by PCR using pHBV3091 as a template (<xref ref-type="bibr" rid="b34">34</xref>). The amplified HBx DNA was cloned into pcDNA3 vector harboring FLAG epitope sequence (pcDNA3-FLAG). The deletion mutant of HBx (&#x00394;73-120) was constructed by inserting the recombinant PCR-generated fragment from the HBx DNA into the pcDNA3-FLAG vector. The expression vectors for the full-length ER&#x003b1; (1&#x02013;595), ER&#x003b1; AF1 (1&#x02013;185), ER&#x003b1; DBD (180&#x02013;282), ER&#x003b1; AF2 (282-595), ER&#x003b1; AF2 (302&#x02013;595) and ER&#x00394;5 (370 amino acids with a novel five-amino acid residue COOH terminus) were made by introducing the corresponding cDNAs into pcDNA3 (Invitrogen). Enhanced green fluorescent protein (EGFP)-tagged HBx construct was generated by inserting HBx DNA into pEGFP-C1 (Clontech), and red fluorescent protein (RFP)-tagged ER&#x003b1; construct by inserting ER&#x003b1; cDNA into pDsRed-N1 (Clontech). A cDNA fragment encoding entire coding region of HDAC1 was obtained by RT&#x02013;PCR using as a template total RNA from the human hepatoma cell line HepG2, and the cDNA fragment was inserted in frame into a pcDNA3 vector linked with HA tag at the amino terminus. Plasmids encoding GST-fusion proteins were prepared by amplification of each sequence by standard PCR methods, and the resulting fragments were cloned in frame into pGEX-KG (Amersham Pharmacia Biotech) using appropriate restriction sites. All of the constructs were confirmed by sequencing. Details of cloning are available upon request.</p></sec><sec><title>Transfection and luciferase assay</title><p>HepG2 and SMMC-7721 cells were routinely grown in DMEM (Invitrogen) supplemented with 10% fetal bovine serum (FBS). For transfection, cells were seeded in 12-well plates containing phenol red-free DMEM medium supplemented with 10% charcoal-stripped FBS (Hyclone). The cells were transfected using Lipofectamine 2000 (Invitrogen) with 0.2 &#x000b5;g of ERE-LUC, C3-LUC, pS2-LUC or pS2&#x00394;ERE-LUC reporter plasmid, 50 ng of ER&#x003b1; expression plasmid, 250 ng to 2 &#x000b5;g of the expression vector for HBx and 0.1 &#x000b5;g of &#x003b2;-galactosidase reporter as an internal control. The empty vector pcDNA3 was used to adjust the total amount of DNA. After treatment with 10 nM of 17&#x003b2;-estradiol (E<sub>2</sub>) and 100 nM 4-hydroxytamoxifen (4-OHT) for 24 h, or 100 nM trichostatin A (TSA) for 12 h, the cells were harvested, and luciferase and &#x003b2;-galactosidase activities were determined as described previously (<xref ref-type="bibr" rid="b35">35</xref>). All experiments were repeated at least five times.</p></sec><sec><title>GST pull-down assay</title><p>GST and GST-fusion proteins were expressed in <italic>E.coli</italic> DH5&#x003b1;, with the induction of protein expression performed at 20&#x000b0;C overnight (<xref ref-type="bibr" rid="b36">36</xref>). After large-scale preparation, purification of the recombinant proteins were performed according to the manufacturer's instruction (Pharmacia) using glutathione&#x02013;Sepharose beads. The expression plasmid for the ER&#x003b1;, ER&#x003b1; deletion mutants, HBx or HDAC1 was used for <italic>in vitro</italic> transcription and translation in the TNT System (Promega). The <sup>35</sup>S-labeled <italic>in vitro</italic> translated products were incubated with &#x0223c;10 &#x000b5;g of GST derivatives bound to glutathione&#x02013;Sepharose beads in 500 &#x000b5;l binding buffer (50 mM Tris&#x02013;HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 0.3 mM DTT, 0.1% NP-40 and protease inhibitor tablets from Roche) at 4&#x000b0;C. The beads were precipitated, washed four times with binding buffer, eluted in SDS&#x02013;PAGE sample buffer, and analyzed by SDS&#x02013;PAGE. After electrophoresis, the gel was dried and exposed to X-ray films.</p></sec><sec><title>Coimmunoprecipitation</title><p>HepG2 cells were transfected with the indicated plasmids using Lipofectamine 2000 (Invitrogen), washed with phosphate-buffered saline (PBS), lysed in 0.5 ml lysis buffer (50 mM Tris, pH 8.0, 250 mM NaCl, 0.25% NP-40, 1 mM DTT and protease inhibitor tablets from Roche), and immunoprecipitated with anti-FLAG-agarose beads (Sigma) for 3 h at 4&#x000b0;C. The beads were centrifuged, washed four times with the lysis buffer, and eluted in 30 &#x000b5;l of SDS&#x02013;PAGE sample buffer. The eluted proteins were separated by SDS&#x02013;PAGE, followed by immunoblotting with anti-ER&#x003b1; (Santa Cruz Biotech), anti-HA (Sigma) or anti-FLAG (Sigma) according to the standard procedures.</p><p>For reimmunoprecipitation, the immune complexes precipitated with anti-FLAG were eluted under native condition by a competition with 3&#x000d7; FLAG peptide according to the manufacturer's instructions (Sigma). The eluate was precleared with 20 &#x000b5;l of 50% protein A agarose beads (Santa Cruz Biotech) for 30 min. Proteins were reprecipitated with anti-ER&#x003b1; or control serum (Santa Cruz Biotech) plus 20 &#x000b5;l of protein A agarose beads. Reprecipitates were washed four times with lysis buffer, eluted by boiling in SDS&#x02013;PAGE sample buffer, and resolved by SDS&#x02013;PAGE, followed by immunoblotting.</p><p>For detecting interaction of endogenous HBx with ER&#x003b1;, liver tissue from an HBV positive patient (General Hospital of PLA, Beijing) was lysed in 1.0 ml RIPA buffer (PBS, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS and protease inhibitor tablets from Roche), and immunoprecipitated with anti-ER&#x003b1; or control serum (Santa Cruz). After extensive washing with RIPA buffer, the immunoprecipitates were resolved by SDS&#x02013;PAGE, followed by western blot analysis using anti-HBx (Chemicon).</p></sec><sec><title>Confocal microscopy</title><p>HepG2 cells were seeded in 6-well dishes with glass coverslips containing phenol red-free DMEM medium (Invitrogen) supplemented with 10% charcoal-stripped FBS (Hyclone). Cells were transiently transfected with the indicated plasmids using lipofectamine 2000. Six hours after transfection, cells were treated with 10 nM of 17&#x003b2;-estradiol (E<sub>2</sub>) for various times. Nuclear DNA was visualized with 4&#x02032;,6&#x02032;-diamidino-2-phenylindole (DAPI). The subcellular localization of EGFP-HBx and RFP-ER&#x003b1; was analyzed with a Radiance 2100 confocal microscope (Bio-Rad). Fluorescence was detected with appropriate filter sets (the green signal, excitation 488 nm, dichroic mirror 560 DCLPXR, emission HQ 515/30; the red signal, excitation 543 nm, dichroic mirror 650 DCLPXR, emission HQ590/70).</p></sec></sec><sec><title>RESULTS</title><sec><title>Repression of ER&#x003b1; transcriptional activity by ER&#x00394;5</title><p>To examine the effects of wt ER and the ER variant ER&#x00394;5 on E<sub>2</sub>-responsive gene transcription, ER&#x003b1;&#x02212;negative human liver carcinoma HepG2 cells (<xref ref-type="bibr" rid="b37">37</xref>) were transiently transfected with wt ER&#x003b1; and/or ER&#x00394;5, along with the synthetic estrogen-responsive reporter plasmid ERE-LUC, or the natural estrogen-responsive reporters pS2-Luc and Complement 3-Luc (C3-Luc). As shown in <xref ref-type="fig" rid="fig1">Figure 1</xref>, in the presence of E<sub>2</sub>, ER&#x003b1; stimulated the transcription of these reporter genes, whereas ER&#x00394;5 had little effect. Importantly, when wt ER and ER&#x00394;5 were co-transfected into the HepG2 cells in equal amounts, ER&#x00394;5 was able to reduce the transcriptional activity of wt ER. These data suggest that ER&#x00394;5 is able to interfere with the transcriptional activity of wt ER and to act as a dominant negative receptor.</p></sec><sec><title>Interaction of ER&#x003b1; with ER&#x00394;5 <italic>in vitro</italic> and <italic>in vivo</italic></title><p>The dominant negative property of the ER variant ER&#x00394;5 could involve the formation of a heterodimer between ER&#x00394;5 and wt ER&#x003b1; through protein&#x02013;protein interactions. To test this possibility, GST pull-down experiments were performed in which <italic>in vitro</italic> translated <sup>35</sup>S-methionine-labeled ER&#x00394;5 was incubated with full-length GST-ER&#x003b1; or GST. As shown in <xref ref-type="fig" rid="fig1">Figure 1B</xref>, in both the absence and presence of E<sub>2</sub>, ER&#x00394;5 bound to GST-ER&#x003b1;, but not to GST, suggesting that ER&#x003b1; physically interacts with ER&#x00394;5 in <italic>vitro</italic>.</p><p>To determine whether ER&#x00394;5 interacted with ER&#x003b1; <italic>in vivo</italic>, HepG2 cells were transfected with ER&#x003b1; and FLAG-tagged ER&#x00394;5, and grown both in the absence and presence of 10 nM E<sub>2</sub>. The cells were then subjected to immunoprecipitation (IP) with FLAG antibody-conjugated agarose beads, followed by immunoblot (IB) with ER&#x003b1; antibody, which recognizes both ER&#x003b1; and ER&#x00394;5 proteins. As shown in <xref ref-type="fig" rid="fig1">Figure 1C</xref>, ER&#x003b1; could be co-immunoprecipitated in a ligand-independent manner in the presence, but not in the absence, of FLAG- ER&#x00394;5. These results suggest that ER&#x00394;5 interacts with ER&#x003b1; in hepatoma cells.</p></sec><sec><title>Repression of ER&#x003b1; transcriptional activity by HBx</title><p>To gain insight into the functional role of HBx in HCC, the effect of HBx protein on ER&#x003b1; transactivation function was investigated. HepG2 cells were co-transfected with the synthetic estrogen response element (ERE)-containing reporter ERE-LUC, ER&#x003b1;, and increasing amounts of HBx. As shown in <xref ref-type="fig" rid="fig2">Figure 2A</xref>, as little as 250 ng of HBx was sufficient to exert a potent repression of ER&#x003b1; transactivation function and the extent of repression increased with increasing amount of HBx expression, suggesting that HBx decreased ER&#x003b1; transcriptional activity in a dose-dependent manner. Similar repression was observed in other liver cancer cells such as SMMC-7721 (data not shown). It should be noted that the decreased transcriptional activity was not a result of reduced ER&#x003b1; protein production (<xref ref-type="fig" rid="fig2">Figure 2B</xref>).</p><p>To test the effect of HBx on natural estrogen-responsive promoter activity, HepG2 cells were co-transfected with the natural ERE-containing reporter C3-Luc or pS2-Luc, together with expression vectors for ER&#x003b1; and HBx. As shown in <xref ref-type="fig" rid="fig2">Figure 2C and D</xref>, activation of the C3 promoter by ER&#x003b1; was not affected by HBx, whereas activation of the pS2 promoter by ER&#x003b1; was significantly repressed by HBx, indicating that the effect of HBx is promoter specific. Interestingly, mutations of the EREs at the pS2 promoter abolished both the E<sub>2</sub>-dependent gene activation and HBx-mediated repression (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). A similar repressive effect of HBx on ER&#x003b1;-mediated transcription was also observed in SMMC-7721 cells (data not shown). As another control of the effects of HBx on transcription, HBx stimulated Smad-mediated gene transcription as reported previously (<xref ref-type="bibr" rid="b38">38</xref>), when HepG2 cells were co-transfected with the synthetic TGF&#x003b2;-responsive transcriptional reporter p3TP-Lux (data not shown). Taken together, our data suggest that specific <italic>cis</italic>- and <italic>trans</italic>-acting elements are required for the HBx-mediated repression.</p></sec><sec><title>Additive repression of specific ER&#x003b1; responsive gene transcription by HBx and ER&#x00394;5</title><p>Since both HBx and ER&#x00394;5 repressed ER&#x003b1; transcriptional activity, we determined if HBx and ER&#x00394;5 had synergistic or additive effect on ER&#x003b1; transactivation. We co-transfected HepG2 cells with the ERE-Luc, C3-Luc, pS2-Luc or pS2&#x00394;ERE-Luc reporter construct, together with HBx or ER&#x00394;5 or in combination. As expected, HBx alone inhibited the transcription of the ERE-Luc and pS2-LUC reporter genes but not the C3-Luc and pS2&#x00394;ERE-Luc reporter genes. ER&#x00394;5 alone repressed the transcription of all of reporter genes except pS2&#x00394;ERE-Luc (<xref ref-type="fig" rid="fig3">Figure 3A&#x02013;D</xref>). Cotransfection with HBx plus ER&#x00394;5 expression vectors gave an additive effect in repressing the transcription of the pS2-LUC reporter gene but not the other reporter genes. These results indicate that the additive effect of HBx and ER&#x00394;5 on ER&#x003b1;-responsive gene transcription is promoter specific.</p><p>To examine the effect of antiestrogen on suppression of ER&#x003b1; transactivation by HBx and ER&#x00394;5, HepG2 cells were co-transfected with the pS2-Luc reporter, ER&#x003b1;, and HBx or ER&#x00394;5 or in combination, and subsequently treated with the antiestrogen 4-OHT (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). 4-OHT alone did not have significant effect on HBx- or ER&#x00394;5-mediated repression, whereas combination of 17&#x003b2;-estradiol (E<sub>2</sub>) and 4-OHT inhibited E<sub>2</sub>-induced ER&#x003b1; transactivation regardless of HBx and ER&#x00394;5.</p></sec><sec><title>Interaction of HBx with ER&#x003b1; <italic>in vitro</italic> and <italic>in vivo</italic></title><p>HBx has been shown to regulate viral and cellular gene transcription by interacting with transcription factors (<xref ref-type="bibr" rid="b3">3</xref>&#x02013;<xref ref-type="bibr" rid="b6">6</xref>). Our observation that HBx could function as a co-repressor to repress ER&#x003b1; transactivation raised the possibility that HBx might physically interact with ER&#x003b1;. To test this possibility, GST pull-down experiments were performed using <sup>35</sup>S-labeled full-length ER&#x003b1; and GST-tagged full-length HBx. As shown in <xref ref-type="fig" rid="fig4">Figure 4A</xref>, GST-HBx, but not GST, was able to pull down the <sup>35</sup>S-labeled ER&#x003b1;, thus demonstrating an <italic>in vitro</italic> interaction between HBx and ER&#x003b1;.</p><p>To test if HBx binds to ER&#x003b1; in mammalian cells, HepG2 cells were transfected with ER&#x003b1; and FLAG-tagged HBx, and harvested for coimmunoprecipitation experiments. <xref ref-type="fig" rid="fig4">Figure 4B</xref> demonstrates that ER&#x003b1; could be co-immunoprecipitated in a ligand-independent manner in the presence of FLAG-HBx but not FLAG-tagged empty vector. To ascertain the HBx&#x02013;ER&#x003b1; interaction in a more physiological context, the endogenous ER&#x003b1; protein from liver tissue of an HBV positive patient was immunoprecipitated with an anti-ER&#x003b1; antibody. Subsequent immunoblotting with anti-HBx antibody indicated that the endogenous HBx was coprecipitated with ER&#x003b1; (<xref ref-type="fig" rid="fig4">Figure 4C</xref>). In the negative control experiment, normal rabbit serum or an irrelevant antibody, anti-FLAG antibody, did not immunoprecipitate HBx (<xref ref-type="fig" rid="fig4">Figure 4C</xref> and data not shown). Taken together, these data strongly suggest that HBx interacts with ER&#x003b1; <italic>in vivo</italic>.</p><p>Since HBx and ER&#x00394;5 have additive effect on the ER&#x003b1; transactivation (<xref ref-type="fig" rid="fig3">Figure 3C</xref>), the effect of ER&#x00394;5 on the HBx&#x02013;ER&#x003b1; interaction was investigated. HepG2 cells were transfected with FLAG-tagged HBx, ER&#x003b1;, and increasing amounts of ER&#x00394;5, and collected for coimmunoprecipitation assays. As shown in <xref ref-type="fig" rid="fig4">Figure 4D</xref>, Both ER&#x003b1; and ER&#x00394;5 were coprecipitated with FLAG-tagged HBx, but not FLAG control vector. Consistent with the functional results (<xref ref-type="fig" rid="fig3">Figure 3C</xref>), ER&#x00394;5 had little effect on the interaction of ER&#x003b1; with HBx (<xref ref-type="fig" rid="fig4">Figure 4D</xref>).</p></sec><sec><title>Co-localization of ER&#x003b1; with HBx</title><p>To confirm the protein&#x02013;protein interaction between HBx and ER&#x003b1; <italic>in situ</italic>, constructs were made for EGFP-tagged HBx (EGFP-HBx) and RFP-tagged ER&#x003b1;. Based on their ability to regulate the ERE-Luc reporter activity, these fluorescent protein-tagged constructs were similar to those with or without the above mentioned FLAG tag (data not shown). HepG2 cells were then co-transfected with EGFP-HBx and RFP-ER&#x003b1;, and analyzed for co-localization of ER&#x003b1; with HBx. As expected, EGFP-HBx localizes in both the cytoplasm and the nucleus of HepG2 cells (<xref ref-type="bibr" rid="b39">39</xref>) (<xref ref-type="fig" rid="fig4">Figure 4E</xref>). RFP-ER&#x003b1; localizes essentially in the nucleus of HepG2 cells in both the presence and absence of estrogen (<xref ref-type="fig" rid="fig4">Figure 4E</xref> and data not shown). Co-localization studies indicated that EGFP-HBx colocalized with RFP-ER&#x003b1;, but not with the empty vector RFP, predominantly in the cell nucleus in a ligand-independent manner, suggesting that ER&#x003b1; may facilitate the nuclear localization of HBx (<xref ref-type="fig" rid="fig4">Figure 4E</xref> and data not shown).</p></sec><sec><title>Mapping of the ER&#x003b1; and HBx interaction regions</title><p>To define the interacting region(s) of HBx on ER&#x003b1;, GST-fusion proteins containing various regions of HBx were prepared and the ability of each of these to interact with <sup>35</sup>S-methionine-labeled <italic>in vitro</italic> translated full-length ER&#x003b1; were determined by GST pull-down assay (<xref ref-type="fig" rid="fig4">Figure 4F</xref>). Deletion of only the first 51 or last 11 amino acids of HBx did not affect the ability to interact with ER&#x003b1;. The GST-HBx(73&#x02013;120) containing part of the transactivation domain bound specifically to ER&#x003b1;, but the GST-HBx(1&#x02013;72) and the GST-HBx(121&#x02013;154) did not.</p><p>To map the domain of ER&#x003b1; responsible for interaction with HBx, a series of <sup>35</sup>S-methionine-labeled <italic>in vitro</italic> translated ER&#x003b1; mutants were used in GST pull-down experiments (<xref ref-type="fig" rid="fig4">Figure 4G</xref>). The ER&#x003b1;(282&#x02013;595) and the ER&#x003b1;(302&#x02013;595) containing the AF2 domain were found to associate with HBx, whereas the ER&#x003b1;(1&#x02013;185) containing the AF1 and the ER&#x003b1;(180&#x02013;282) containing the DBD did not. ER&#x00394;5, which has amino acid residues 1&#x02013;365 of ER&#x003b1; also interacted with HBx, although with weak binding affinity.</p></sec><sec><title>Interaction of HBx with ER&#x003b1; is required for inhibition of ER&#x003b1; transactivation function</title><p>To test the possibility that the interaction of HBx with ER&#x003b1; is required for the repression of ER&#x003b1; transactivation function, the HBx mutant [HBx(&#x00394;73&#x02013;120)] in which the interaction region from amino acids 73 to 120 of HBx was deleted was constructed. HepG2 cells were co-transfected with the ERE-LUC reporter, ER&#x003b1;, and FLAG-tagged full-length HBx or HBx(&#x00394;73&#x02013;120). As shown in <xref ref-type="fig" rid="fig5">Figure 5A</xref>, the mutation lacking the ER&#x003b1;-binding site abrogated the repression of ER&#x003b1; transactivation function by HBx. Notably, FLAG-tagged HBx and HBx(&#x00394;73&#x02013;120) were expressed at comparable levels (<xref ref-type="fig" rid="fig5">Figure 5B</xref>). To determine if HBx(&#x00394;73&#x02013;120) did lose the ability to interact with ER&#x003b1; in HepG2 cells, coimmunoprecipitation experiments were performed. As expected, HBx(&#x00394;73&#x02013;120) did not interact with ER&#x003b1; (<xref ref-type="fig" rid="fig5">Figure 5C</xref>). Taken together, these findings suggest that interaction of HBx with ER&#x003b1; is required for repression of ER&#x003b1; transactivation function.</p></sec><sec><title>HBx, ER&#x003b1; and HDAC1 form a complex</title><p>To investigate whether the observed repression of ER&#x003b1;-responsive gene transcription by HBx was associated with recruitment of HDAC complexes, we examined the interaction between HBx and HDAC1 by GST pull-down assay. As shown in <xref ref-type="fig" rid="fig6">Figure 6A</xref>, <italic>in vitro</italic> translated HDAC1 interacted with GST-HBx, but not with GST alone, indicating that HBx associated with HDAC1 <italic>in vitro</italic>.</p><p>To determine whether the interaction of HBx with HDAC1 occurred <italic>in vivo</italic>, we performed coimmunoprecipitation and immunoblotting (<xref ref-type="fig" rid="fig6">Figure 6B</xref>). Transient expression of FLAG-tagged HBx, but not control FLAG vector, in HepG2 cells was accompanied by interaction with HA-tagged HDAC1. These results suggest that HBx interacts with HDAC1 <italic>in vivo</italic>.</p><p>To examine whether HBx, ER&#x003b1; and HDAC1 formed a complex, HepG2 cells were transfected with ER&#x003b1; and HA-tagged HDAC1 with or without FLAG-tagged HBx. The cells were then subjected to immunoprecipitation with FLAG antibody-conjugated agarose beads, followed by immunoblot with ER&#x003b1; and HA antibodies (<xref ref-type="fig" rid="fig6">Figure 6C</xref>). Both ER&#x003b1; and HDAC1 were coprecipitated with FLAG-tagged HBx, but not FLAG control vector. To further confirm the possibility of a ternary complex among HBx, ER&#x003b1;, and HDAC1, the immune complexes precipitated with FLAG antibody were eluted with a FLAG peptide, and subjected to a second immunoprecipitation with an anti-ER&#x003b1; antibody. The anti-ER&#x003b1; immunoprecipitates were then subjected to immunoblotting with anti-HA to detect HA-tagged HDAC1. HA-tagged HDAC1 was present after sequential immunoprecipitation (<xref ref-type="fig" rid="fig6">Figure 6D</xref>). In contrast, HA-tagged HDAC1 was absent after a second immunoprecipitation with control antibody. These data provide strong evidence that HBx, ER&#x003b1; and HDAC1 together can form a ternary complex <italic>in vivo</italic>.</p></sec><sec><title>HDAC inhibitor relieves repression of ER&#x003b1; transactivation function by HBx</title><p>Our observation that HBx interacts with HDAC1 raises the possibility that the repression of ER&#x003b1; functions by HBx could be HDAC dependent. To this end, we examined the effect of TSA, a specific inhibitor of HDAC enzyme, on HBx-induced repression of ERE transcription in HepG2 cells (<xref ref-type="fig" rid="fig7">Figure 7</xref>). We found that HBx-mediated repression of ER&#x003b1; transcriptional activity could be effectively relieved by inhibiting HDAC activity. Interestingly, E<sub>2</sub> and TSA have additive or synergistic effect in stimulating ER&#x003b1; transcriptional activity. These data suggest that HBx may recruit HDAC enzyme to repress ERE-mediated transcription.</p></sec></sec><sec><title>DISCUSSION</title><p>In the present study, we demonstrated for the first time that both ER&#x00394;5 and HBx can inhibit ER&#x003b1; transcriptional activity in human liver cancer cells. We found that the repression of ER&#x003b1; transactivation function by ER&#x00394;5 and HBx is mediated by their physical interaction with ER&#x003b1;. The binding of HBx with ER&#x003b1; is important for HBx-induced repression of ER&#x003b1; transactivation function because the HBx deletion mutant that lacks ER&#x003b1;-binding site completely abolished the repression of ER&#x003b1; transcriptional activity by HBx. Furthermore, we have shown that ER&#x00394;5 and HBx have additive but not synergistic effect on repression of ER&#x003b1;-responsive gene transcription, suggesting that ER&#x00394;5, ER&#x003b1; and HBx may not form a complex.</p><p>Estrogen has been reported to promote the growth of certain human neoplasms, notably tumors of the breast, endometrium and pituitary (<xref ref-type="bibr" rid="b40">40</xref>,<xref ref-type="bibr" rid="b41">41</xref>). In sharp contrast, Estrogen was shown to suppress the replication of HBV that has been clearly recognized as a major etiological factor for HCC (<xref ref-type="bibr" rid="b13">13</xref>). Studies of chemical carcinogenesis also suggested that ER&#x003b1; may modulate HCC risk by inhibiting the malignant transformation of pre-neoplastic liver cells. The ER&#x003b1; variant ER&#x00394;5 was shown to be preferentially expressed in patients with HCC compared with parents with normal livers and to be associated with poor clinical outcome (<xref ref-type="bibr" rid="b25">25</xref>&#x02013;<xref ref-type="bibr" rid="b28">28</xref>). Therefore, it is important to determine whether the ER&#x00394;5 is able to interfere with the transcriptional activity of wt ER&#x003b1;. When ER&#x00394;5 was expressed alone in human ER&#x003b1;-negative hepatoma HepG2 cells, it had little effect on either basal or E<sub>2</sub>-mediated ERE-containing reporter activity. However, when ER&#x00394;5 was coexpressed with wt ER&#x003b1;, the reporter activity was significantly decreased, similar to that in human breast cancer cells (<xref ref-type="bibr" rid="b42">42</xref>). Our data suggest that ER&#x00394;5 functions as a dominant negative receptor in human liver cancer cells. Although both in breast and liver cancer cells, ER&#x00394;5 displays dominant negative activity, ER&#x00394;5 was found to act as a dominant positive receptor isoform and facilitate both basal and E<sub>2</sub>-stimulated ERE-mediated transcription of wt ER&#x003b1; when coexpressed in ER&#x003b1;-negative human osteosarcoma U2-OS and human endometrial cancer Ishikawa cells (<xref ref-type="bibr" rid="b43">43</xref>,<xref ref-type="bibr" rid="b44">44</xref>). These discordant results could be due to the different cell types used, suggesting that some factors required for ER&#x003b1; transcriptional activity may be tissue specific.</p><p>A number of studies have shown that HBx interacts with proteins involved in transcriptional regulation (<xref ref-type="bibr" rid="b3">3</xref>&#x02013;<xref ref-type="bibr" rid="b5">5</xref>,<xref ref-type="bibr" rid="b45">45</xref>). Most of the studies identify HBx as a co-activator of transcription. For example, HBx enhances the transcription efficacy of the CREB transcription factor through interaction with CREB (<xref ref-type="bibr" rid="b46">46</xref>). HBx associates with hypoxia inducible factor-1&#x003b1; (HIF-1&#x003b1;), a major transcriptional factor that regulates expression of angiogenic factors such as vascular endothelial growth factor (VEGF), and enhances the transactivation function of HIF-1&#x003b1; (<xref ref-type="bibr" rid="b47">47</xref>,<xref ref-type="bibr" rid="b48">48</xref>). HBx was also shown to stimulate transcription by activating cellular signal transduction pathways. For instance, HBx is involved in activating Wnt/&#x003b2;-catenin signaling by stabilizing cytoplasmic &#x003b2;-catenin. HBx can stimulate activator protein 1 (AP-1) via two distinct pathways, the Ras-Raf-mitogen-activated protein kinase (MAPK) and the c-Jun amino-terminal kinase (JNK) cascades (<xref ref-type="bibr" rid="b49">49</xref>). On the other hand, HBx was found to act as a co-repressor of transcription. HBx interferes with p53 by direct binding and by sequestering p53 in the cytoplasm, resulting in the abrogation of p53-mediated transcriptional activity (<xref ref-type="bibr" rid="b6">6</xref>). HBx binds to DBD of peroxisome proliferator-activated receptor &#x003b3; (PPAR&#x003b3;), a member of the steroid hormone receptor superfamily, and suppresses PPAR&#x003b3;-mediated transactivation (<xref ref-type="bibr" rid="b50">50</xref>). Our results showed that HBx represses ER&#x003b1; transcriptional activity through interaction with ER&#x003b1; and recruitment of HDAC1, which belongs to a class of enzymes involved in deacetylation of hyperacetylated histone tails, leading to compaction of chromatin and transcriptional repression (<xref ref-type="bibr" rid="b51">51</xref>). Importantly, the inhibitory effect of HBx on ER&#x003b1; transcriptional activity was antagonized by the HDAC inhibitor TSA. Interestingly, E<sub>2</sub> and TSA are additive or synergistic in inducing ER&#x003b1; transcriptional activity. The fact that HBx represses ER&#x003b1; transcriptional activity in the presence or absence of E<sub>2</sub> suggests that HBx regulates ER&#x003b1; transcriptional activity in a ligand-independent manner. Recently, the tumor suppressor BRCA1 has been shown to mediate ligand-independent transcriptional repression of ER&#x003b1; in a manner dependent on HDAC activity (<xref ref-type="bibr" rid="b52">52</xref>). Our observation that HBx, ER&#x003b1; and HDAC1 can form a complex and TSA can effectively reverse ligand-independent repression mediated by HBx suggests that one of the underlying mechanisms by which HBx mediates ligand-independent repression of ER&#x003b1; transcriptional activity may involve targeted recruitment by unliganded, promoter-bound ER&#x003b1; of a HBx-associated HDAC activity.</p><p>Tamoxifen is considered to be relatively more estrogenic than antiestrogenic in the urine, bone and liver tissues (<xref ref-type="bibr" rid="b37">37</xref>). Thus, tamoxifen has been used for the treatment of liver cancer. Indeed, initial studies with a relatively small population of patients with HCC show regression of liver tumor mass and improved survival in some of the tamoxifen-treated patients (<xref ref-type="bibr" rid="b53">53</xref>). However, more and more recent controlled trials with this drug were disappointing (<xref ref-type="bibr" rid="b54">54</xref>&#x02013;<xref ref-type="bibr" rid="b56">56</xref>). Tamoxifen does not prolong survival in patients with HCC and has an increasingly negative impact with increasing dose. There is also no appreciable advantage to quality of life with tamoxifen. These studies showed conclusively that, although the mechanisms by which tamoxifen negatively impacts HCC are not known, tamoxifen does not benefit patients with HCC and is likely to be detrimental. Thus, the use of tamoxifen in patients with HCC is not recommended. Our study indicated that 4-OHT, a metabolite of the tamoxifen with a more potent estrogen agonist/antagonist activity than tamoxifen, acts as a pure estrogen antagonist in HepG2 cells, which is in agreement with the previous study showing that tamoxifen functions as a pure estrogen antagonist in HepG2 cells (<xref ref-type="bibr" rid="b37">37</xref>). This may at least in part explain why tamoxifen is ineffective in the treatment of HCC.</p><p>Recently, HDAC inhibitors have been used successfully to inhibit cancer cell growth <italic>in vitro</italic> and <italic>in vivo</italic> (<xref ref-type="bibr" rid="b57">57</xref>&#x02013;<xref ref-type="bibr" rid="b59">59</xref>). TSA specifically inhibits classes I and II HDACs by binding directly to their catalytic site (<xref ref-type="bibr" rid="b3">3</xref>). Class I HDACs include HDAC1, HDAC2, HDAC3, HDAC8 and HDAC11, and Class II HDACs include HDACs 4&#x02013;7 and HDACs 9&#x02013;10. TSA regulates the expression of small subsets of growth-related genes and has potent antitumor activity <italic>in vitro</italic> and <italic>in vivo</italic>. In hepatoma cells, TSA induces a G<sub>2</sub>/M cell cycle arrest followed by apoptosis (<xref ref-type="bibr" rid="b60">60</xref>,<xref ref-type="bibr" rid="b61">61</xref>). Since E<sub>2</sub> and TSA are additive or synergistic in inducing ER&#x003b1; transcriptional activity in hepatoma cells, it is important to develop more effective therapeutic agents for HCC that increase ER&#x003b1; transactivation function, with no obvious side effects.</p></sec></body><back><ack><p>We thank Xuemin Zhang for technical assistance. This work was supported by the Key Technologies R&#x00026;D Program (2002BA711A02-5) and National Natural Science Foundation (30571655, 30530320 and 30428012). Funding to pay the Open Access publication charges for this article was provided by the Key Technologies R&#x00026;D Program.</p><p><italic>Conflict of interest statement</italic>. None declared.</p></ack><ref-list><title>REFERENCES</title><ref id="b1"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>W.M.</given-names></name></person-group><article-title>Hepatitis B virus infection</article-title><source>N. Engl. J. Med.</source><year>1997</year><volume>337</volume><fpage>1733</fpage><lpage>1745</lpage><pub-id pub-id-type="pmid">9392700</pub-id></citation></ref><ref id="b2"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murakami</surname><given-names>S.</given-names></name></person-group><article-title>Hepatitis B virus X protein: a multifunctional viral regulator</article-title><source>J. Gastroenterol.</source><year>2001</year><volume>6</volume><fpage>651</fpage><lpage>660</lpage><pub-id pub-id-type="pmid">11686474</pub-id></citation></ref><ref id="b3"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cheong</surname><given-names>J.H.</given-names></name><name><surname>Yi</surname><given-names>M.</given-names></name><name><surname>Lin</surname><given-names>Y.</given-names></name><name><surname>Murakami</surname><given-names>S.</given-names></name></person-group><article-title>Human RPB5, a subunit shared by eukaryotic nuclear RNA polymerases, binds human hepatitis B virus X protein and may play a role in X transactivation</article-title><source>EMBO J.</source><year>1995</year><volume>14</volume><fpage>143</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">7828586</pub-id></citation></ref><ref id="b4"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Qadri</surname><given-names>I.</given-names></name><name><surname>Maguire</surname><given-names>H.F.</given-names></name><name><surname>Siddiqui</surname><given-names>A.</given-names></name></person-group><article-title>Hepatitis B virus transactivator protein X interacts with the TATA-binding protein</article-title><source>Proc. Natl Acad. Sci. USA</source><year>1995</year><volume>92</volume><fpage>1003</fpage><lpage>1007</lpage><pub-id pub-id-type="pmid">7862623</pub-id></citation></ref><ref id="b5"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perini</surname><given-names>G.</given-names></name><name><surname>Oetjen</surname><given-names>E.</given-names></name><name><surname>Green</surname><given-names>M.R.</given-names></name></person-group><article-title>The hepatitis B pX protein promotes dimerization and DNA binding of cellular basic region/leucine zipper proteins by targeting the conserved basic region</article-title><source>J. Biol. Chem.</source><year>1999</year><volume>274</volume><fpage>13970</fpage><lpage>13977</lpage><pub-id pub-id-type="pmid">10318808</pub-id></citation></ref><ref id="b6"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X.W.</given-names></name><name><surname>Forrester</surname><given-names>K.</given-names></name><name><surname>Yeh</surname><given-names>H.</given-names></name><name><surname>Feitelson</surname><given-names>M.A.</given-names></name><name><surname>Gu</surname><given-names>J.R.</given-names></name><name><surname>Harris</surname><given-names>C.C.</given-names></name></person-group><article-title>Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3</article-title><source>Proc. Natl Acad. Sci. USA</source><year>1994</year><volume>91</volume><fpage>2230</fpage><lpage>2234</lpage><pub-id pub-id-type="pmid">8134379</pub-id></citation></ref><ref id="b7"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Takada</surname><given-names>S.</given-names></name><name><surname>Kido</surname><given-names>H.</given-names></name><name><surname>Fukutomi</surname><given-names>A.</given-names></name><name><surname>Mori</surname><given-names>T.</given-names></name><name><surname>Koike</surname><given-names>K.</given-names></name></person-group><article-title>Interaction of hepatitis B virus X protein with a serine protease, tryptase TL2 as an inhibitor</article-title><source>Oncogene</source><year>1994</year><volume>9</volume><fpage>341</fpage><lpage>348</lpage><pub-id pub-id-type="pmid">8290248</pub-id></citation></ref><ref id="b8"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>T.H.</given-names></name><name><surname>Elledge</surname><given-names>S.J.</given-names></name><name><surname>Butel</surname><given-names>J.S.</given-names></name></person-group><article-title>Hepatitis B virus X protein interacts with a probable cellular DNA repair protein</article-title><source>J. Virol.</source><year>1995</year><volume>69</volume><fpage>1107</fpage><lpage>1114</lpage><pub-id pub-id-type="pmid">7815490</pub-id></citation></ref><ref id="b9"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brechot</surname><given-names>C.</given-names></name><name><surname>Jaffredo</surname><given-names>F.</given-names></name><name><surname>Lagorce</surname><given-names>D.</given-names></name><name><surname>Gerken</surname><given-names>G.</given-names></name><name><surname>Meyer zum Buschenfelde</surname><given-names>K.</given-names></name><name><surname>Papakonstontinou</surname><given-names>A.</given-names></name><name><surname>Hadziyannis</surname><given-names>S.</given-names></name><name><surname>Romeo</surname><given-names>R.</given-names></name><name><surname>Colombo</surname><given-names>M.</given-names></name><name><surname>Rodes</surname><given-names>J.</given-names></name><etal/></person-group><article-title>Impact of HBV, HCV and GBV-C/HGV on hepatocellular carcinomas in Europe: results of a European concerted action</article-title><source>J. Hepatol.</source><year>1998</year><volume>29</volume><fpage>173</fpage><lpage>183</lpage><pub-id pub-id-type="pmid">9722197</pub-id></citation></ref><ref id="b10"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kew</surname><given-names>M.C.</given-names></name></person-group><article-title>Increasing evidence that hepatitis B virus X gene protein and p53 protein may interact in the pathogenesis of hepatocellular carcinoma</article-title><source>Hepatology</source><year>1997</year><volume>25</volume><fpage>1037</fpage><lpage>1038</lpage><pub-id pub-id-type="pmid">9096618</pub-id></citation></ref><ref id="b11"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Murakami</surname><given-names>S.</given-names></name></person-group><article-title>Hepatitis B virus X protein: structure, function and biology</article-title><source>Intervirology</source><year>1999</year><volume>42</volume><fpage>81</fpage><lpage>99</lpage><pub-id pub-id-type="pmid">10516464</pub-id></citation></ref><ref id="b12"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>C.T.</given-names></name></person-group><article-title>Hepatitis B virus X protein: searching for a role in hepatocarcinogenesis</article-title><source>J. Gastroenterol. Hepatol.</source><year>2000</year><volume>15</volume><fpage>339</fpage><lpage>341</lpage><pub-id pub-id-type="pmid">10824873</pub-id></citation></ref><ref id="b13"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Almog</surname><given-names>Y.</given-names></name><name><surname>Klein</surname><given-names>A.</given-names></name><name><surname>Adler</surname><given-names>R.</given-names></name><name><surname>Laub</surname><given-names>O.</given-names></name><name><surname>Tur-Kaspa</surname><given-names>R.</given-names></name></person-group><article-title>Estrogen suppresses hepatitis B virus expression in male athymic mice transplanted with HBV transfected HepG-2 cells</article-title><source>Antiviral Res.</source><year>1992</year><volume>19</volume><fpage>285</fpage><lpage>293</lpage><pub-id pub-id-type="pmid">1463321</pub-id></citation></ref><ref id="b14"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>C.J.</given-names></name><name><surname>Yu</surname><given-names>M.W.</given-names></name><name><surname>Liaw</surname><given-names>Y.F.</given-names></name></person-group><article-title>Epidemiological characteristics and risk factors of hepatocellular carcinoma</article-title><source>J. Gastroenterol. Hepatol.</source><year>1997</year><volume>12</volume><fpage>S294</fpage><lpage>308</lpage><pub-id pub-id-type="pmid">9407350</pub-id></citation></ref><ref id="b15"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>M.W.</given-names></name><name><surname>Chen</surname><given-names>C.J.</given-names></name></person-group><article-title>Hepatitis B and C viruses in the development of hepatocellular carcinoma</article-title><source>Crit. Rev. Oncol. Hematol.</source><year>1994</year><volume>17</volume><fpage>71</fpage><lpage>91</lpage><pub-id pub-id-type="pmid">7818788</pub-id></citation></ref><ref id="b16"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>M.C.</given-names></name><name><surname>Tong</surname><given-names>M.J.</given-names></name><name><surname>Govindarajan</surname><given-names>S.</given-names></name><name><surname>Henderson</surname><given-names>B.E.</given-names></name></person-group><article-title>Nonviral risk factors for hepatocellular carcinoma in a low-risk population, the non-Asians of Los Angeles County, California</article-title><source>J. Natl Cancer. Inst.</source><year>1991</year><volume>83</volume><fpage>1820</fpage><lpage>1826</lpage><pub-id pub-id-type="pmid">1660542</pub-id></citation></ref><ref id="b17"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Maria</surname><given-names>N.</given-names></name><name><surname>Manno</surname><given-names>M.</given-names></name><name><surname>Villa</surname><given-names>E.</given-names></name></person-group><article-title>Sex hormones and liver cancer</article-title><source>Mol. Cell. Endocrinol.</source><year>2002</year><volume>193</volume><fpage>59</fpage><lpage>63</lpage><pub-id pub-id-type="pmid">12161002</pub-id></citation></ref><ref id="b18"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kuiper</surname><given-names>G.G.</given-names></name><name><surname>Enmark</surname><given-names>E.</given-names></name><name><surname>Pelto-Huikko</surname><given-names>M.</given-names></name><name><surname>Nilsson</surname><given-names>S.</given-names></name><name><surname>Gustafsson</surname><given-names>J.A.</given-names></name></person-group><article-title>Cloning of a novel receptor expressed in rat prostate and ovary</article-title><source>Proc. Natl Acad. Sci.USA</source><year>1996</year><volume>93</volume><fpage>5925</fpage><lpage>5930</lpage><pub-id pub-id-type="pmid">8650195</pub-id></citation></ref><ref id="b19"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kuiper</surname><given-names>G.G.</given-names></name><name><surname>Carlsson</surname><given-names>B.</given-names></name><name><surname>Grandien</surname><given-names>K.</given-names></name><name><surname>Enmark</surname><given-names>E.</given-names></name><name><surname>Haggblad</surname><given-names>J.</given-names></name><name><surname>Nilsson</surname><given-names>S.</given-names></name><name><surname>Gustafsson</surname><given-names>J.A.</given-names></name></person-group><article-title>Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors &#x003b1; and &#x003b2;</article-title><source>Endocrinology</source><year>1997</year><volume>138</volume><fpage>863</fpage><lpage>870</lpage><pub-id pub-id-type="pmid">9048584</pub-id></citation></ref><ref id="b20"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Katzenellenbogen</surname><given-names>B.S.</given-names></name><name><surname>Katzenellenbogen</surname><given-names>J.A.</given-names></name></person-group><article-title>Estrogen receptor transcription and transactivation: estrogen receptor &#x003b1; and estrogen receptor &#x003b2;: regulation by selective estrogen receptor modulators and importance in breast cancer</article-title><source>Breast Cancer Res.</source><year>2000</year><volume>2</volume><fpage>335</fpage><lpage>344</lpage><pub-id pub-id-type="pmid">11250726</pub-id></citation></ref><ref id="b21"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Klinge</surname><given-names>C.M.</given-names></name></person-group><article-title>Estrogen receptor interaction with co-activators and co-repressors</article-title><source>Steroids</source><year>2000</year><volume>65</volume><fpage>227</fpage><lpage>251</lpage><pub-id pub-id-type="pmid">10751636</pub-id></citation></ref><ref id="b22"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Eisenfeld</surname><given-names>A.J.</given-names></name><name><surname>Aten</surname><given-names>R.</given-names></name><name><surname>Weinberger</surname><given-names>M.</given-names></name><name><surname>Haselbacher</surname><given-names>G.</given-names></name><name><surname>Halpern</surname><given-names>K.</given-names></name><name><surname>Krakoff</surname><given-names>L.</given-names></name></person-group><article-title>Estrogen receptor in the mammalian liver</article-title><source>Science</source><year>1976</year><volume>191</volume><fpage>862</fpage><lpage>865</lpage><pub-id pub-id-type="pmid">175442</pub-id></citation></ref><ref id="b23"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Porter</surname><given-names>L.E.</given-names></name><name><surname>Elm</surname><given-names>M.S.</given-names></name><name><surname>Van Thiel</surname><given-names>D.H.</given-names></name><name><surname>Dugas</surname><given-names>M.C.</given-names></name><name><surname>Eagon</surname><given-names>P.K.</given-names></name></person-group><article-title>Characterization and quantitation of human hepatic estrogen receptor</article-title><source>Gastroenterology</source><year>1983</year><volume>84</volume><fpage>704</fpage><lpage>712</lpage><pub-id pub-id-type="pmid">6825981</pub-id></citation></ref><ref id="b24"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rossini</surname><given-names>G.P.</given-names></name><name><surname>Baldini</surname><given-names>G.M.</given-names></name><name><surname>Villa</surname><given-names>E.</given-names></name><name><surname>Manenti</surname><given-names>F.</given-names></name></person-group><article-title>Characterization of estrogen receptor from human liver</article-title><source>Gastroenterology</source><year>1989</year><volume>96</volume><fpage>1102</fpage><lpage>1109</lpage><pub-id pub-id-type="pmid">2925054</pub-id></citation></ref><ref id="b25"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Villa</surname><given-names>E.</given-names></name><name><surname>Camellini</surname><given-names>L.</given-names></name><name><surname>Dugani</surname><given-names>A.</given-names></name><name><surname>Zucchi</surname><given-names>F.</given-names></name><name><surname>Grottola</surname><given-names>A.</given-names></name><name><surname>Merighi</surname><given-names>A.</given-names></name><name><surname>Buttafoco</surname><given-names>P.</given-names></name><name><surname>Losi</surname><given-names>L.</given-names></name><name><surname>Manenti</surname><given-names>F.</given-names></name></person-group><article-title>Variant estrogen receptor messenger RNA species detected in human primary hepatocellular carcinoma</article-title><source>Cancer Res.</source><year>1995</year><volume>55</volume><fpage>498</fpage><lpage>500</lpage><pub-id pub-id-type="pmid">7834616</pub-id></citation></ref><ref id="b26"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Villa</surname><given-names>E.</given-names></name><name><surname>Dugani</surname><given-names>A.</given-names></name><name><surname>Fantoni</surname><given-names>E.</given-names></name><name><surname>Camellini</surname><given-names>L.</given-names></name><name><surname>Buttafoco</surname><given-names>P.</given-names></name><name><surname>Grottola</surname><given-names>A.</given-names></name><name><surname>Pompei</surname><given-names>G.</given-names></name><name><surname>De Santis</surname><given-names>M.</given-names></name><name><surname>Ferrari</surname><given-names>A.</given-names></name><name><surname>Manenti</surname><given-names>F.</given-names></name></person-group><article-title>Type of estrogen receptor determines response to antiestrogen therapy</article-title><source>Cancer Res.</source><year>1996</year><volume>56</volume><fpage>3883</fpage><lpage>3885</lpage><pub-id pub-id-type="pmid">8752151</pub-id></citation></ref><ref id="b27"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Villa</surname><given-names>E.</given-names></name><name><surname>Moles</surname><given-names>A.</given-names></name><name><surname>Ferretti</surname><given-names>I.</given-names></name><name><surname>Buttafoco</surname><given-names>P.</given-names></name><name><surname>Grottola</surname><given-names>A.</given-names></name><name><surname>Del Buono</surname><given-names>M.</given-names></name><name><surname>De Santis</surname><given-names>M.</given-names></name><name><surname>Manenti</surname><given-names>F.</given-names></name></person-group><article-title>Natural history of inoperable hepatocellular carcinoma: estrogen receptors' status in the tumor is the strongest prognostic factor for survival</article-title><source>Hepatology</source><year>2000</year><volume>32</volume><fpage>233</fpage><lpage>238</lpage><pub-id pub-id-type="pmid">10915729</pub-id></citation></ref><ref id="b28"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Villa</surname><given-names>E.</given-names></name><name><surname>Colantoni</surname><given-names>A.</given-names></name><name><surname>Camma</surname><given-names>C.</given-names></name><name><surname>Grottola</surname><given-names>A.</given-names></name><name><surname>Buttafoco</surname><given-names>P.</given-names></name><name><surname>Gelmini</surname><given-names>R.</given-names></name><name><surname>Ferretti</surname><given-names>I.</given-names></name><name><surname>Manenti</surname><given-names>F.</given-names></name></person-group><article-title>Estrogen receptor classification for hepatocellular carcinoma: comparison with clinical staging systems</article-title><source>J. Clin. Oncol.</source><year>2003</year><volume>21</volume><fpage>441</fpage><lpage>446</lpage><pub-id pub-id-type="pmid">12560432</pub-id></citation></ref><ref id="b29"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>L.</given-names></name><name><surname>Yan</surname><given-names>J.</given-names></name><name><surname>Zhu</surname><given-names>J.</given-names></name><name><surname>Zhong</surname><given-names>H.</given-names></name><name><surname>Lu</surname><given-names>Q.</given-names></name><name><surname>Wang</surname><given-names>Z.</given-names></name><name><surname>Huang</surname><given-names>C.</given-names></name><name><surname>Ye</surname><given-names>Q.</given-names></name></person-group><article-title>Ligand-independent activation of estrogen receptor &#x003b1; by XBP-1</article-title><source>Nucleic Acids Res.</source><year>2003</year><volume>31</volume><fpage>5266</fpage><lpage>5274</lpage><pub-id pub-id-type="pmid">12954762</pub-id></citation></ref><ref id="b30"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fan</surname><given-names>J.D.</given-names></name><name><surname>Wagner</surname><given-names>B.L.</given-names></name><name><surname>McDonnell</surname><given-names>D.P.</given-names></name></person-group><article-title>Identification of the sequences within the human complement 3 promoter required for estrogen responsiveness provides insight into the mechanism of tamoxifen mixed agonist activity</article-title><source>Mol. Endocrinol.</source><year>1996</year><volume>10</volume><fpage>1605</fpage><lpage>1616</lpage><pub-id pub-id-type="pmid">8961270</pub-id></citation></ref><ref id="b31"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Aiyar</surname><given-names>S.E.</given-names></name><name><surname>Sun</surname><given-names>J.L.</given-names></name><name><surname>Blair</surname><given-names>A.L.</given-names></name><name><surname>Moskaluk</surname><given-names>C.A.</given-names></name><name><surname>Lu</surname><given-names>Y.Z.</given-names></name><name><surname>Ye</surname><given-names>Q.N.</given-names></name><name><surname>Yamaguchi</surname><given-names>Y.</given-names></name><name><surname>Mukherjee</surname><given-names>A.</given-names></name><name><surname>Ren</surname><given-names>D.M.</given-names></name><name><surname>Handa</surname><given-names>H.</given-names></name><etal/></person-group><article-title>Attenuation of estrogen receptor &#x003b1;-mediated transcription through estrogen-stimulated recruitment of a negative elongation factor</article-title><source>Genes Dev.</source><year>2004</year><volume>18</volume><fpage>2134</fpage><lpage>2146</lpage><pub-id pub-id-type="pmid">15342491</pub-id></citation></ref><ref id="b32"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Green</surname><given-names>S.</given-names></name><name><surname>Chambon</surname><given-names>P.</given-names></name></person-group><article-title>A superfamily of potentially oncogenic hormone receptors</article-title><source>Nature</source><year>1986</year><volume>324</volume><fpage>615</fpage><lpage>617</lpage><pub-id pub-id-type="pmid">3025739</pub-id></citation></ref><ref id="b33"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tremblay</surname><given-names>G.B.</given-names></name><name><surname>Tremblay</surname><given-names>A.</given-names></name><name><surname>Copeland</surname><given-names>N.G.</given-names></name><name><surname>Gilbert</surname><given-names>D.J.</given-names></name><name><surname>Jenkins</surname><given-names>N.A.</given-names></name><name><surname>Labrie</surname><given-names>F.</given-names></name><name><surname>Giguere</surname><given-names>V.</given-names></name></person-group><article-title>Cloning, chromosomal localization, and functional analysis of the murine estrogen receptor &#x003b2;</article-title><source>Mol. Endocrinol.</source><year>1997</year><volume>11</volume><fpage>353</fpage><lpage>365</lpage><pub-id pub-id-type="pmid">9058381</pub-id></citation></ref><ref id="b34"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Protzer</surname><given-names>U.</given-names></name><name><surname>Nassal</surname><given-names>M.</given-names></name><name><surname>Chiang</surname><given-names>P.W.</given-names></name><name><surname>Kirschfink</surname><given-names>M.</given-names></name><name><surname>Schaller</surname><given-names>H.</given-names></name></person-group><article-title>Interferon gene transfer by a hepatitis B virus vector efficiently suppresses wild-type virus infection</article-title><source>Proc. Natl Acad. Sci. USA</source><year>1999</year><volume>96</volume><fpage>10818</fpage><lpage>10823</lpage><pub-id pub-id-type="pmid">10485909</pub-id></citation></ref><ref id="b35"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>Q.</given-names></name><name><surname>Chung</surname><given-names>L.W.</given-names></name><name><surname>Cinar</surname><given-names>B.</given-names></name><name><surname>Li</surname><given-names>S.</given-names></name><name><surname>Zhau</surname><given-names>H.E.</given-names></name></person-group><article-title>Identification and characterization of estrogen receptor variants in prostate cancer cell lines</article-title><source>J. Steroid Biochem. Mol. Biol.</source><year>2000</year><volume>75</volume><fpage>21</fpage><lpage>31</lpage><pub-id pub-id-type="pmid">11179905</pub-id></citation></ref><ref id="b36"><label>36</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ye</surname><given-names>Q.</given-names></name><name><surname>Hu</surname><given-names>Y.F.</given-names></name><name><surname>Zhong</surname><given-names>H.</given-names></name><name><surname>Nye</surname><given-names>A.C.</given-names></name><name><surname>Belmont</surname><given-names>A.S.</given-names></name><name><surname>Li</surname><given-names>R.</given-names></name></person-group><article-title>BRCA1-induced large-scale chromatin unfolding and allele-specific effects of cancer-predisposing mutations</article-title><source>J. Cell Biol.</source><year>2001</year><volume>155</volume><fpage>911</fpage><lpage>921</lpage><pub-id pub-id-type="pmid">11739404</pub-id></citation></ref><ref id="b37"><label>37</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Barkhem</surname><given-names>T.</given-names></name><name><surname>Andersson-Ross</surname><given-names>C.</given-names></name><name><surname>Hoglund</surname><given-names>M.</given-names></name><name><surname>Nilsson</surname><given-names>S.</given-names></name></person-group><article-title>Characterization of the &#x02018;estrogenicity&#x02019; of tamoxifen and raloxifene in HepG2 cells: regulation of gene expression from an ERE controlled reporter vector versus regulation of the endogenous SHBG and PS2 genes</article-title><source>J. Steroid Biochem. Mol. Biol.</source><year>1997</year><volume>62</volume><fpage>53</fpage><lpage>64</lpage><pub-id pub-id-type="pmid">9366498</pub-id></citation></ref><ref id="b38"><label>38</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>D.K.</given-names></name><name><surname>Park</surname><given-names>S.H.</given-names></name><name><surname>Yi</surname><given-names>Y.</given-names></name><name><surname>Choi</surname><given-names>S.G.</given-names></name><name><surname>Lee</surname><given-names>C.</given-names></name><name><surname>Parks</surname><given-names>W.T.</given-names></name><name><surname>Cho</surname><given-names>H.</given-names></name><name><surname>de Caestecker</surname><given-names>M.P.</given-names></name><name><surname>Shaul</surname><given-names>Y.</given-names></name><name><surname>Roberts</surname><given-names>A.B.</given-names></name><etal/></person-group><article-title>The hepatitis B virus encoded oncoprotein pX amplifies TGF-beta family signaling through direct interaction with Smad4: potential mechanism of hepatitis B virus-induced liver fibrosis</article-title><source>Genes Dev.</source><year>2001</year><volume>15</volume><fpage>455</fpage><lpage>466</lpage><pub-id pub-id-type="pmid">11230153</pub-id></citation></ref><ref id="b39"><label>39</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bontron</surname><given-names>S.</given-names></name><name><surname>Lin-Marq</surname><given-names>N.</given-names></name><name><surname>Strubin</surname><given-names>M.</given-names></name></person-group><article-title>Hepatitis B virus X protein associated with UV-DDB1 induces cell death in the nucleus and is functionally antagonized by UV-DDB2</article-title><source>J. Biol. Chem.</source><year>2002</year><volume>277</volume><fpage>38847</fpage><lpage>38854</lpage><pub-id pub-id-type="pmid">12151405</pub-id></citation></ref><ref id="b40"><label>40</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Curtis Hewitt</surname><given-names>S.</given-names></name><name><surname>Couse</surname><given-names>J.F.</given-names></name><name><surname>Korach</surname><given-names>K.S.</given-names></name></person-group><article-title>Estrogen receptor transcription and transactivation: estrogen receptor knockout mice: what their phenotypes reveal about mechanisms of estrogen action</article-title><source>Breast Cancer Res.</source><year>2000</year><volume>2</volume><fpage>345</fpage><lpage>352</lpage><pub-id pub-id-type="pmid">11250727</pub-id></citation></ref><ref id="b41"><label>41</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McDonnell</surname><given-names>D.P.</given-names></name><name><surname>Norris</surname><given-names>J.D.</given-names></name></person-group><article-title>Connections and regulation of the human estrogen receptor</article-title><source>Science</source><year>2002</year><volume>296</volume><fpage>1642</fpage><lpage>1644</lpage><pub-id pub-id-type="pmid">12040178</pub-id></citation></ref><ref id="b42"><label>42</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ohlsson</surname><given-names>H.</given-names></name><name><surname>Lykkesfeldt</surname><given-names>A.E.</given-names></name><name><surname>Madsen</surname><given-names>M.W.</given-names></name><name><surname>Briand</surname><given-names>P.</given-names></name></person-group><article-title>The estrogen receptor variant lacking exon 5 has dominant negative activity in the human breast epithelial cell line HMT-3522S1</article-title><source>Cancer Res.</source><year>1998</year><volume>58</volume><fpage>4264</fpage><lpage>4268</lpage><pub-id pub-id-type="pmid">9766649</pub-id></citation></ref><ref id="b43"><label>43</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chaidarun</surname><given-names>S.S.</given-names></name><name><surname>Alexander</surname><given-names>J.M.</given-names></name></person-group><article-title>A tumor-specific truncated estrogen receptor splice variant enhances estrogen-stimulated gene expression</article-title><source>Mol. Endocrinol.</source><year>1998</year><volume>12</volume><fpage>1355</fpage><lpage>1366</lpage><pub-id pub-id-type="pmid">9731704</pub-id></citation></ref><ref id="b44"><label>44</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bryant</surname><given-names>W.</given-names></name><name><surname>Snowhite</surname><given-names>A.E.</given-names></name><name><surname>Rice</surname><given-names>L.W.</given-names></name><name><surname>Shupnik</surname><given-names>M.A.</given-names></name></person-group><article-title>The estrogen receptor (ER)&#x003b1; variant &#x00394;5 exhibits dominant positive activity on ER-regulated promoters in endometrial carcinoma cells</article-title><source>Endocrinology</source><year>2005</year><volume>146</volume><fpage>751</fpage><lpage>759</lpage><pub-id pub-id-type="pmid">15528307</pub-id></citation></ref><ref id="b45"><label>45</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Haviv</surname><given-names>I.</given-names></name><name><surname>Shamay</surname><given-names>M.</given-names></name><name><surname>Doitsh</surname><given-names>G.</given-names></name><name><surname>Shaul</surname><given-names>Y.</given-names></name></person-group><article-title>Hepatitis B virus pX targets TFIIB in transcription coactivation</article-title><source>Mol. Cell. Biol.</source><year>1998</year><volume>18</volume><fpage>1562</fpage><lpage>1569</lpage><pub-id pub-id-type="pmid">9488473</pub-id></citation></ref><ref id="b46"><label>46</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Williams</surname><given-names>J.S.</given-names></name><name><surname>Andrisani</surname><given-names>O.M.</given-names></name></person-group><article-title>The hepatitis B virus X protein targets the basic region-leucine zipper domain of CREB</article-title><source>Proc. Natl Acad. Sci. USA</source><year>1995</year><volume>92</volume><fpage>3819</fpage><lpage>3823</lpage><pub-id pub-id-type="pmid">7731990</pub-id></citation></ref><ref id="b47"><label>47</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yoo</surname><given-names>Y.G.</given-names></name><name><surname>Oh</surname><given-names>S.H.</given-names></name><name><surname>Park</surname><given-names>E.S.</given-names></name><name><surname>Cho</surname><given-names>H.</given-names></name><name><surname>Lee</surname><given-names>N.</given-names></name><name><surname>Park</surname><given-names>H.</given-names></name><name><surname>Kim</surname><given-names>D.K.</given-names></name><name><surname>Yu</surname><given-names>D.Y.</given-names></name><name><surname>Seong</surname><given-names>J.K.</given-names></name><name><surname>Lee</surname><given-names>M.O.</given-names></name></person-group><article-title>Hepatitis B virus X protein enhances transcriptional activity of hypoxia-inducible factor-1alpha through activation of mitogen-activated protein kinase pathway</article-title><source>J. Biol. Chem.</source><year>2003</year><volume>278</volume><fpage>39076</fpage><lpage>39084</lpage><pub-id pub-id-type="pmid">12855680</pub-id></citation></ref><ref id="b48"><label>48</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moon</surname><given-names>E.J.</given-names></name><name><surname>Jeong</surname><given-names>C.H.</given-names></name><name><surname>Jeong</surname><given-names>J.W.</given-names></name><name><surname>Kim</surname><given-names>K.R.</given-names></name><name><surname>Yu</surname><given-names>D.Y.</given-names></name><name><surname>Murakami</surname><given-names>S.</given-names></name><name><surname>Kim</surname><given-names>C.W.</given-names></name><name><surname>Kim</surname><given-names>K.W.</given-names></name></person-group><article-title>Hepatitis B virus X protein induces angiogenesis by stabilizing hypoxia-inducible factor-1&#x003b1;</article-title><source>FASEB J.</source><year>2004</year><volume>18</volume><fpage>382</fpage><lpage>384</lpage><pub-id pub-id-type="pmid">14688211</pub-id></citation></ref><ref id="b49"><label>49</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cha</surname><given-names>M.Y.</given-names></name><name><surname>Kim</surname><given-names>C.M.</given-names></name><name><surname>Park</surname><given-names>Y.M.</given-names></name><name><surname>Ryu</surname><given-names>W.S.</given-names></name></person-group><article-title>Hepatitis B virus X protein is essential for the activation of Wnt/&#x003b2;-catenin signaling in hepatoma cells</article-title><source>Hepatology</source><year>2004</year><volume>39</volume><fpage>1683</fpage><lpage>1693</lpage><pub-id pub-id-type="pmid">15185310</pub-id></citation></ref><ref id="b50"><label>50</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Choi</surname><given-names>Y.H.</given-names></name><name><surname>Kim</surname><given-names>H.I.</given-names></name><name><surname>Seong</surname><given-names>J.K.</given-names></name><name><surname>Yu</surname><given-names>D.Y.</given-names></name><name><surname>Cho</surname><given-names>H.</given-names></name><name><surname>Lee</surname><given-names>M.O.</given-names></name><name><surname>Lee</surname><given-names>J.M.</given-names></name><name><surname>Ahn</surname><given-names>Y.H.</given-names></name><name><surname>Kim</surname><given-names>S.J.</given-names></name><name><surname>Park</surname><given-names>J.H.</given-names></name></person-group><article-title>Hepatitis B virus X protein modulates peroxisome proliferator-activated receptor &#x003b3; through protein-protein interaction</article-title><source>FEBS Lett.</source><year>2004</year><volume>557</volume><fpage>73</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">14741344</pub-id></citation></ref><ref id="b51"><label>51</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xue</surname><given-names>Y.</given-names></name><name><surname>Wong</surname><given-names>J.</given-names></name><name><surname>Moreno</surname><given-names>G.T.</given-names></name><name><surname>Young</surname><given-names>M.K.</given-names></name><name><surname>Cote</surname><given-names>J.</given-names></name><name><surname>Wang</surname><given-names>W.</given-names></name></person-group><article-title>NURD, a novel complex with both ATP-dependent chromatin-remodeling and histone deacetylase activities</article-title><source>Mol. Cell</source><year>1998</year><volume>2</volume><fpage>851</fpage><lpage>861</lpage><pub-id pub-id-type="pmid">9885572</pub-id></citation></ref><ref id="b52"><label>52</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>Lei.</given-names></name><name><surname>Annab</surname><given-names>L.A.</given-names></name><name><surname>Afshari</surname><given-names>C.A.</given-names></name><name><surname>Lee</surname><given-names>W.H.</given-names></name><name><surname>Boyer</surname><given-names>T.G.</given-names></name></person-group><article-title>BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor</article-title><source>Proc. Natl Acad. Sci. USA</source><year>2001</year><volume>98</volume><fpage>9587</fpage><lpage>9592</lpage><pub-id pub-id-type="pmid">11493692</pub-id></citation></ref><ref id="b53"><label>53</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Martinez Cerezo</surname><given-names>F.J.</given-names></name><name><surname>Tomas</surname><given-names>A.</given-names></name><name><surname>Donoso</surname><given-names>L.</given-names></name><name><surname>Enriquez</surname><given-names>J.</given-names></name><name><surname>Guarner</surname><given-names>C.</given-names></name><name><surname>Balanzo</surname><given-names>J.</given-names></name><name><surname>Martinez Nogueras</surname><given-names>A.</given-names></name><name><surname>Vilardell</surname><given-names>F.</given-names></name></person-group><article-title>Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma</article-title><source>J. Hepatol.</source><year>1994</year><volume>20</volume><fpage>702</fpage><lpage>706</lpage><pub-id pub-id-type="pmid">7930468</pub-id></citation></ref><ref id="b54"><label>54</label><citation citation-type="other"><collab>[No authors listed]</collab><article-title>Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. CLIP Group (Cancer of the Liver Italian Programme).</article-title><source>Lancet</source><year>1998</year><volume>352</volume><fpage>17</fpage><lpage>20</lpage></citation></ref><ref id="b55"><label>55</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perrone</surname><given-names>F.</given-names></name><name><surname>Gallo</surname><given-names>C.</given-names></name><name><surname>Daniele</surname><given-names>B.</given-names></name><name><surname>Gaeta</surname><given-names>G.B.</given-names></name><name><surname>Izzo</surname><given-names>F.</given-names></name><name><surname>Capuano</surname><given-names>G.</given-names></name><name><surname>Adinolfi</surname><given-names>L.E.</given-names></name><name><surname>Mazzanti</surname><given-names>R.</given-names></name><name><surname>Farinati</surname><given-names>F.</given-names></name><name><surname>Elba</surname><given-names>S.</given-names></name><etal/></person-group><article-title>Tamoxifen in the treatment of hepatocellular carcinoma: 5-year results of the CLIP-1 multicentre randomised controlled trial</article-title><source>Curr. Pharm. Des.</source><year>2002</year><volume>8</volume><fpage>1013</fpage><lpage>1019</lpage><pub-id pub-id-type="pmid">11945148</pub-id></citation></ref><ref id="b56"><label>56</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chow</surname><given-names>P.K.</given-names></name><name><surname>Tai</surname><given-names>B.C.</given-names></name><name><surname>Tan</surname><given-names>C.K.</given-names></name><name><surname>Machin</surname><given-names>D.</given-names></name><name><surname>Win</surname><given-names>K.M.</given-names></name><name><surname>Johnson</surname><given-names>P.J.</given-names></name><name><surname>Soo</surname><given-names>K.C.</given-names></name></person-group><article-title>High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: a multicenter randomized controlled trial</article-title><source>Hepatology</source><year>2002</year><volume>36</volume><fpage>1221</fpage><lpage>1226</lpage><pub-id pub-id-type="pmid">12395333</pub-id></citation></ref><ref id="b57"><label>57</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kramer</surname><given-names>O.H.</given-names></name><name><surname>Gottlicher</surname><given-names>M.</given-names></name><name><surname>Heinzel</surname><given-names>T.</given-names></name></person-group><article-title>Histone deacetylase as a therapeutic target</article-title><source>Trends Endocrinol. Metab.</source><year>2001</year><volume>12</volume><fpage>294</fpage><lpage>300</lpage><pub-id pub-id-type="pmid">11504668</pub-id></citation></ref><ref id="b58"><label>58</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jung</surname><given-names>M.</given-names></name></person-group><article-title>Inhibitors of histone deacetylase as new anticancer agents</article-title><source>Curr. Med. Chem.</source><year>2001</year><volume>8</volume><fpage>1505</fpage><lpage>1511</lpage><pub-id pub-id-type="pmid">11562279</pub-id></citation></ref><ref id="b59"><label>59</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Finnin</surname><given-names>M.S.</given-names></name><name><surname>Donigian</surname><given-names>J.R.</given-names></name><name><surname>Cohen</surname><given-names>A.</given-names></name><name><surname>Richon</surname><given-names>V.M.</given-names></name><name><surname>Rifkind</surname><given-names>R.A.</given-names></name><name><surname>Marks</surname><given-names>P.A.</given-names></name><name><surname>Breslow</surname><given-names>R.</given-names></name><name><surname>Pavletich</surname><given-names>N.P.</given-names></name></person-group><article-title>Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors</article-title><source>Nature</source><year>1999</year><volume>401</volume><fpage>188</fpage><lpage>193</lpage><pub-id pub-id-type="pmid">10490031</pub-id></citation></ref><ref id="b60"><label>60</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Herold</surname><given-names>C.</given-names></name><name><surname>Ganslmayer</surname><given-names>M.</given-names></name><name><surname>Ocker</surname><given-names>M.</given-names></name><name><surname>Hermann</surname><given-names>M.</given-names></name><name><surname>Geerts</surname><given-names>A.</given-names></name><name><surname>Hahn</surname><given-names>E.G.</given-names></name><name><surname>Schuppan</surname><given-names>D.</given-names></name></person-group><article-title>The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells</article-title><source>J. Hepatol.</source><year>2002</year><volume>36</volume><fpage>233</fpage><lpage>240</lpage><pub-id pub-id-type="pmid">11830335</pub-id></citation></ref><ref id="b61"><label>61</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yamashita</surname><given-names>Y.</given-names></name><name><surname>Shimada</surname><given-names>M.</given-names></name><name><surname>Harimoto</surname><given-names>N.</given-names></name><name><surname>Rikimaru</surname><given-names>T.</given-names></name><name><surname>Shirabe</surname><given-names>K.</given-names></name><name><surname>Tanaka</surname><given-names>S.</given-names></name><name><surname>Sugimachi</surname><given-names>K.</given-names></name></person-group><article-title>Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells</article-title><source>Int. J. Cancer</source><year>2003</year><volume>103</volume><fpage>572</fpage><lpage>576</lpage><pub-id pub-id-type="pmid">12494463</pub-id></citation></ref></ref-list><sec sec-type="display-objects"><title>Figures and Tables</title><fig id="fig1" position="float"><label>Figure 1</label><caption><p>ER&#x00394;5 represses ER&#x003b1; transcriptional activity through interaction with ER&#x003b1;. (<bold>A</bold>) ER&#x00394;5 represses transcription of the ERE-Luc, pS2-Luc and C3-Luc reporters. HepG2 cells were co-transfected with 0.5 &#x000b5;g of the expression vector for ER&#x00394;5, 0.5 &#x000b5;g of the expression plasmid for ER&#x003b1; and 0.2 &#x000b5;g of various luciferase reporter plasmids in the absence or presence of 10 nM of 17&#x003b2;-estradiol (E<sub>2</sub>). The luciferase activity obtained on transfection of the respective luciferase reporter and ER&#x003b1; without exogenous ER&#x00394;5 in the absence of E<sub>2</sub> was set as 1. (<bold>B</bold>) <italic>In vitro</italic> interaction of ER&#x00394;5 with ER&#x003b1;. Glutathione&#x02013;Sepharose beads bound with GST-ER&#x003b1; or with GST were incubated with <sup>35</sup>S-labeled ER&#x00394;5 in the absence or presence of 100 nM E<sub>2</sub>. After washing the beads, the bound proteins were eluted and subjected to SDS&#x02013;PAGE and autoradiography. (<bold>C</bold>) <italic>In vivo</italic> interaction of ER&#x00394;5 with ER&#x003b1;. ER&#x003b1; and FLAG-tagged ER&#x00394;5 were co-transfected into HepG2 cells in the presence or absence of 10 nM E<sub>2</sub>. Cell lysates were immunoprecipitated (IP) by anti-FLAG M2 monoclonal antibody (Sigma), and the precipitates were then immunoblotted (IB) with anti-ER&#x003b1; polyclonal antibody (Santa Cruz Biotech).</p></caption><graphic xlink:href="gkl389f1"/></fig><fig id="fig2" position="float"><label>Figure 2</label><caption><p>HBx inhibits ER&#x003b1;-mediated transactivation function in hepatoma cells. (<bold>A</bold>) HepG2 cells were co-transfected with 0.2 &#x000b5;g of ERE-Luc, 50 ng of the expression plasmid for ER&#x003b1; and increasing amounts of the expression plasmid for FLAG-tagged HBx in the absence or presence of 10 nM E<sub>2</sub>. The luciferase activity obtained on transfection of ERE-Luc and ER&#x003b1; without exogenous HBx in the absence of E<sub>2</sub> was set as 1. (<bold>B</bold>) Immunoblotting showing the ER&#x003b1; and HBx levels in HepG2 cells. Cells were transfected as in (A). Whole cell extracts were prepared from the cells transfected with 2.0 &#x000b5;g of the expression plasmid for HBx in the presence of 10 nM E<sub>2</sub>, and were detected with anti-ER&#x003b1; (Santa Cruz Biotech), anti-FLAG (Sigma) or anti-GAPDH (Biogenesis) antibody. (C&#x02013;E) HepG2 cells were co-transfected with 50 ng of the expression plasmid for ER&#x003b1;, 1.0 &#x000b5;g of the expression plasmid for FLAG-tagged HBx, and 0.2 &#x000b5;g of C3-Luc (<bold>C</bold>), pS2-Luc (<bold>D</bold>) or pS2&#x00394;ERE-Luc (<bold>E</bold>), in the absence or presence of 10 nM E<sub>2</sub>. The luciferase activity obtained on transfection of the respective luciferase reporter without exogenous ER&#x003b1; and HBx in the absence of E<sub>2</sub> was set as 1.</p></caption><graphic xlink:href="gkl389f2"/></fig><fig id="fig3" position="float"><label>Figure 3</label><caption><p>HBx and ER&#x00394;5 have additive effect on repression of specific ER&#x003b1; responsive gene transcription. (A&#x02013;D) HepG2 cells were co-transfected with 50 ng of the expression plasmid for ER&#x003b1;, 1.0 &#x000b5;g of the expression plasmid for FLAG-tagged HBx, 50 ng of the expression plasmid for ER&#x00394;5, and 0.2 &#x000b5;g of ERE-Luc (<bold>A</bold>), C3-Luc (<bold>B</bold>), pS2-Luc (<bold>C</bold>) or pS2&#x00394;ERE-Luc (<bold>D</bold>), in the absence or presence of 10 nM E<sub>2</sub>. The luciferase activity obtained on transfection of the respective luciferase reporter without exogenous ER&#x003b1;, ER&#x00394;5 and HBx in the absence of E<sub>2</sub> was set as 1. (<bold>E</bold>) HepG2 cells were co-transfected with 0.2 &#x000b5;g of pS2-Luc, 50 ng of the expression plasmid for ER&#x003b1;, 1.0 &#x000b5;g of the expression plasmid for FLAG-tagged HBx and 50 ng of the expression vector for ER&#x00394;5. Cells were then treated with control (0.1% ethanol) vehicle, 10 nM E<sub>2</sub>, 100 nM 4-hydroxytamoxifen (4-OHT) or 10 nM E<sub>2</sub> plus 100 nM 4-OHT. The luciferase activity obtained on transfection of pS2-Luc without exogenous ER&#x003b1;, ER&#x00394;5 and HBx in the absence of E<sub>2</sub> was set as 1.</p></caption><graphic xlink:href="gkl389f3"/></fig><fig id="fig4" position="float"><label>Figure 4</label><caption><p>HBx interacts with ER&#x003b1; <italic>in vitro</italic> and <italic>in vivo</italic>. (<bold>A</bold>) Interaction of HBx with ER&#x003b1; <italic>in vitro</italic>. A GST pull-down assay was performed using <sup>35</sup>S-labeled ER&#x003b1;, and GST or GST-HBx. The bound proteins were subjected to SDS&#x02013;PAGE followed by autoradiography. (<bold>B</bold>) Interaction of HBx with ER&#x003b1; <italic>in vivo</italic>. ER&#x003b1; and FLAG-tagged HBx or empty vector were co-transfected into HepG2 cells. Cell lysates were immunoprecipitated (IP) by anti-FLAG M2 monoclonal antibody (Sigma), and the precipitates were then immunoblotted (IB) with anti-ER&#x003b1; polyclonal antibody (Santa Cruz Biotech). (<bold>C</bold>) Interaction of endogenous HBx with ER&#x003b1; <italic>in vivo</italic>. Liver tissue extracts from an HBV positive patient were immunoprecipitated with either anti-ER&#x003b1; polyclonal antibody or preimmune control serum (Santa Cruz Biotech). The precipitates were analyzed by immunoblot using anti-HBx (Chemicon). (<bold>D</bold>) Effect of ER&#x00394;5 on the interaction between HBx and ER&#x003b1;. HepG2 cells were co-transfected with 2 &#x000b5;g ER&#x003b1;, 4 &#x000b5;g FLAG-tagged HBx and increasing amounts of ER&#x00394;5 (2 and 4 &#x000b5;g). Cell lysates were immunoprecipitated by anti-FLAG monoclonal antibody, and the precipitates were detected with anti-ER&#x003b1; polyclonal antibody. (<bold>E</bold>) Co-localization of HBx and ER&#x003b1; in HepG2 cells. Cells were transfected with EGFP-tagged HBx and RFP-tagged ER&#x003b1; or empty vector (RFP) as indicated, and were treated with 10 nM E<sub>2</sub> for 24 h. The images were captured by confocal immunofluorescence microscopy. HBx localization is shown with EGFP (green) and ER&#x003b1; is seen with RFP (red). The nuclei were stained with DAPI (blue). Co-localization of HBx with ER&#x003b1; is shown in merged images. (<bold>F</bold>) Mapping of the ER&#x003b1; interaction region in HBx. A GST pull-down assay was performed using <sup>35</sup>S-labeled ER&#x003b1; and GST-HBx(1-72), GST-HBx(73-120), GST-HBx(121-154), GST-HBx(1-143), GST-HBx(52-154) and full-length GST-HBx(1&#x02013;154) or GST. Schematic diagram of the HBx deletion constructs used is shown at the top, the binding of ER&#x003b1; to different regions of HBx is demonstrated in the middle, and SDS&#x02013;PAGE analysis of the purified GST-fusion proteins is shown at the bottom. Asterisks indicate the positions of the expected purified GST or GST-fusion proteins. (<bold>G</bold>) Mapping of the HBx interaction region in ER&#x003b1;. A GST pull-down assay was performed using full-length GST-HBx(1&#x02013;154) or GST, and <sup>35</sup>S-labeled full-length ER&#x003b1; (1&#x02013;595), ER&#x003b1; (1&#x02013;185), ER&#x003b1; (180&#x02013;282), ER&#x003b1; (282&#x02013;595), ER&#x003b1; (302&#x02013;595) or ER&#x00394;5. Schematic diagram of the ER&#x003b1; deletion constructs used is shown at the top.</p></caption><graphic xlink:href="gkl389f4"/></fig><fig id="fig5" position="float"><label>Figure 5</label><caption><p>The HBx deletion mutant abolishes HBx-induced repression of ER&#x003b1; transcriptional activity. (<bold>A</bold>) Luciferase reporter assays with the HBx deletion mutants. HepG2 cells were co-transfected with 0.2 &#x000b5;g of ERE-LUC, 50 ng of the expression plasmid for ER&#x003b1; and 1.0 &#x000b5;g of the expression vector for FLAG-tagged HBx or HBx(&#x00394;73&#x02013;120), in the presence or absence of 10 nM E<sub>2</sub>. (<bold>B</bold>) Western blotting showing expression of FLAG-tagged HBx and HBx(&#x00394;73&#x02013;120). Cells were transfected as in (A). Cell extracts were prepared from E<sub>2</sub>-treated cells, and equivalent amounts of each extract were detected with anti-FLAG or anti-GAPDH antibody. (<bold>C</bold>) The HBx deletion mutant abolishes the HBx&#x02013;ER&#x003b1; interaction. HepG2 cells were co-transfected with the expression plasmid for ER&#x003b1; and the expression vector for FLAG-tagged HBx or HBx(&#x00394;73&#x02013;120). Cell lysates were immunoprecipitated by anti-FLAG, and the precipitates were probed with anti-ER&#x003b1;.</p></caption><graphic xlink:href="gkl389f5"/></fig><fig id="fig6" position="float"><label>Figure 6</label><caption><p>HBx forms a complex with ER&#x003b1; and HDAC1. (<bold>A</bold>) Association of HBx with HDAC1 <italic>in vitro</italic>. GST-HBx and GST were incubated with <sup>35</sup>S-labeled ER&#x003b1;, and a GST pull-down assay was then performed. (<bold>B</bold>) Association of HBx with ER&#x003b1; <italic>in vivo</italic>. HepG2 cells were transiently transfected with HA-tagged HDAC1 and FLAG-tagged HBx or control vector. Immunoprecipitation (IP) was performed using anti-FLAG monoclonal antibody; immunoblotting (IB) was performed with the indicated antibodies. (<bold>C</bold>) HBx interacts with both HDAC1 and ER&#x003b1; <italic>in vivo</italic>. HepG2 cells were co-transfected with ER&#x003b1;, HA-tagged HDAC1, and FLAG-tagged HBx or control vector. The cell extracts were immunoprecipitated with anti-FLAG monoclonal antibody followed by immunoblotting with the indicated antibodies. (<bold>D</bold>) HBx, ER&#x003b1; and HDAC1 forms a ternary complex. HepG2 cells were transfected as in (C). The cell extracts were immunoprecipitated with anti-FLAG antibody. Immune complexes were eluted with FLAG peptide and re-immunoprecipitated (re-IP) using anti-ER&#x003b1; polyclonal antibody and normal rabbit serum as a negative control. The resulting precipitates were resolved by SDS&#x02013;PAGE followed by immunoblotting with the indicated antibodies.</p></caption><graphic xlink:href="gkl389f6"/></fig><fig id="fig7" position="float"><label>Figure 7</label><caption><p>Treatment of hepatoma cells with the specific HDAC inhibitor TSA causes a drastic relieving of HBx-induced repression of ER&#x003b1; transactivation. HepG2 cells co-transfected with 0.2 &#x000b5;g of the ERE-Luc reporter, 50 ng of the expression vector for ER&#x003b1;, 1.0 &#x000b5;g of the expression plasmid for HBx. Cells were then treated with control (0.1% ethanol) vehicle, 10 nM E<sub>2</sub> or 100 nM TSA as indicated. The luciferase activity obtained on transfection of ERE-Luc and ER&#x003b1; without exogenous HBx in the absence of E<sub>2</sub> and TSA was set as 1.</p></caption><graphic xlink:href="gkl389f7"/></fig></sec></back></article> 